TY - JOUR AU - Banchereau, J. PY - 2000 DA - 2000// TI - Immunobiology of dendritic cells JO - Annu. Rev. Immunol. VL - 18 UR - https://doi.org/10.1146/annurev.immunol.18.1.767 DO - 10.1146/annurev.immunol.18.1.767 ID - Banchereau2000 ER - TY - JOUR AU - Melief, C. J. PY - 2008 DA - 2008// TI - Cancer immunotherapy by dendritic cells JO - Immunity VL - 29 UR - https://doi.org/10.1016/j.immuni.2008.08.004 DO - 10.1016/j.immuni.2008.08.004 ID - Melief2008 ER - TY - JOUR AU - Valone, F. H. PY - 2001 DA - 2001// TI - Dendritic cell-based treatment of cancer: closing in on a cellular therapy JO - Cancer J. VL - 2 ID - Valone2001 ER - TY - JOUR AU - Engleman, E. G. PY - 2003 DA - 2003// TI - Dendritic cell-based cancer immunotherapy JO - Semin. Oncol. VL - 30 UR - https://doi.org/10.1016/S0093-7754(03)00229-X DO - 10.1016/S0093-7754(03)00229-X ID - Engleman2003 ER - TY - JOUR AU - Mocikat, R. AU - Selmayr, M. AU - Thierfelder, S. AU - Lindhofer, H. PY - 1997 DA - 1997// TI - Trioma-based vaccination against B-cell lymphoma confers long-lasting tumor immunity JO - Cancer Res. VL - 57 ID - Mocikat1997 ER - TY - JOUR AU - Selmayr, M. PY - 1999 DA - 1999// TI - Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype JO - Gene Ther. VL - 6 UR - https://doi.org/10.1038/sj.gt.3300875 DO - 10.1038/sj.gt.3300875 ID - Selmayr1999 ER - TY - JOUR AU - Selmayr, M. AU - Menzel, H. AU - Kremer, J. P. AU - Thierfelder, S. AU - Mocikat, R. PY - 2000 DA - 2000// TI - B-cell lymphoma idiotypes chimerized by gene targeting can induce tumor immunity JO - Cancer Gene Ther. VL - 7 UR - https://doi.org/10.1038/sj.cgt.7700129 DO - 10.1038/sj.cgt.7700129 ID - Selmayr2000 ER - TY - JOUR AU - Graf, N. AU - Adam, C. AU - Mocikat, R. PY - 2003 DA - 2003// TI - Persistence of xenogenized vaccine cells in vivo JO - Int. J. Cancer. VL - 105 UR - https://doi.org/10.1002/ijc.11065 DO - 10.1002/ijc.11065 ID - Graf2003 ER - TY - JOUR AU - Kronenberger, K. PY - 2002 DA - 2002// TI - Impact of the lymphoma idiotype on in vivo tumor protection in a vaccination model based on targeting antigens to antigen-presenting cells JO - Blood VL - 99 UR - https://doi.org/10.1182/blood.V99.4.1327 DO - 10.1182/blood.V99.4.1327 ID - Kronenberger2002 ER - TY - JOUR AU - Peipp, M. AU - Valerius, T. PY - 2002 DA - 2002// TI - Bispecific antibodies targeting cancer cells JO - Biochem. Soc. Trans. VL - 30 UR - https://doi.org/10.1042/bst0300507 DO - 10.1042/bst0300507 ID - Peipp2002 ER - TY - JOUR AU - Chames, P. AU - Baty, D. PY - 2009 DA - 2009// TI - Bispecific antibodies for cancer therapy: the light at the end of the tunnel? JO - MAbs. VL - 1 UR - https://doi.org/10.4161/mabs.1.6.10015 DO - 10.4161/mabs.1.6.10015 ID - Chames2009 ER - TY - JOUR AU - Zeidler, R. PY - 1999 DA - 1999// TI - Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing JO - J. Immunol. VL - 163 UR - https://doi.org/10.4049/jimmunol.163.3.1246 DO - 10.4049/jimmunol.163.3.1246 ID - Zeidler1999 ER - TY - JOUR AU - Zeidler, R. PY - 2000 DA - 2000// TI - The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells JO - Br. J. Cancer. VL - 83 UR - https://doi.org/10.1054/bjoc.2000.1237 DO - 10.1054/bjoc.2000.1237 ID - Zeidler2000 ER - TY - JOUR AU - Ruf, P. AU - Lindhofer, H. PY - 2001 DA - 2001// TI - Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody JO - Blood VL - 98 UR - https://doi.org/10.1182/blood.V98.8.2526 DO - 10.1182/blood.V98.8.2526 ID - Ruf2001 ER - TY - JOUR AU - Eiβler, N. AU - Ruf, P. AU - Mysliwietz, J. AU - Lindhofer, H. AU - Mocikat, R. PY - 2012 DA - 2012// TI - Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect JO - Cancer Res. VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-12-0146 DO - 10.1158/0008-5472.CAN-12-0146 ID - Eiβler2012 ER - TY - JOUR AU - Haraguchi, M. PY - 1994 DA - 1994// TI - Isolation of GD3 synthase gene by expression cloning of GM3 alpha-2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody JO - Proc. Natl. Acad. Sci. U. S. A. VL - 91 UR - https://doi.org/10.1073/pnas.91.22.10455 DO - 10.1073/pnas.91.22.10455 ID - Haraguchi1994 ER - TY - JOUR AU - Schrama, D. PY - 2004 DA - 2004// TI - Shift from systemic to site-specific memory by tumor-targeted IL-2 JO - J. Immunol. VL - 172 UR - https://doi.org/10.4049/jimmunol.172.10.5843 DO - 10.4049/jimmunol.172.10.5843 ID - Schrama2004 ER - TY - JOUR AU - Strehl, J. PY - 1999 DA - 1999// TI - Gene therapy of B-cell lymphoma with cytokine gene-modified trioma cells JO - Int. J. Cancer. VL - 83 UR - https://doi.org/3.0.CO;2-J DO - 3.0.CO;2-J ID - Strehl1999 ER - TY - JOUR AU - Ruf, P. PY - 2004 DA - 2004// TI - Two new trifunctional antibodies for the therapy of human malignant melanoma JO - Int. J. Cancer. VL - 108 UR - https://doi.org/10.1002/ijc.11630 DO - 10.1002/ijc.11630 ID - Ruf2004 ER - TY - JOUR AU - Lindhofer, H. AU - Mocikat, R. AU - Steipe, B. AU - Thierfelder, S. PY - 1995 DA - 1995// TI - Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas: implications for a single-step purification of bispecific antibodies JO - J. Immunol. VL - 155 UR - https://doi.org/10.4049/jimmunol.155.1.219 DO - 10.4049/jimmunol.155.1.219 ID - Lindhofer1995 ER - TY - JOUR AU - Björk, P. PY - 1993 DA - 1993// TI - Isolation, partial characterization, and molecular cloning of a human colon adenocarcinoma cell-surface glycoprotein recognized by the C215 mouse monoclonal antibody JO - J. Biol. Chem. VL - 268 UR - https://doi.org/10.1016/S0021-9258(20)80515-8 DO - 10.1016/S0021-9258(20)80515-8 ID - Björk1993 ER - TY - JOUR AU - Ruf, P. PY - 2012 DA - 2012// TI - Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model JO - J. Transl. Med. VL - 10 UR - https://doi.org/10.1186/1479-5876-10-219 DO - 10.1186/1479-5876-10-219 ID - Ruf2012 ER - TY - CHAP AU - Lindhofer, H. AU - Hess, J. AU - Ruf, P. ED - Kontermann, R. PY - 2011 DA - 2011// TI - Triomab® antibodies for cancer therapy BT - Bispecific Antibodies PB - Springer CY - Heidelberg UR - https://doi.org/10.1007/978-3-642-20910-9_16 DO - 10.1007/978-3-642-20910-9_16 ID - Lindhofer2011 ER - TY - JOUR AU - Hess, J. AU - Ruf, P. AU - Lindhofer, H. PY - 2012 DA - 2012// TI - Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity JO - Future Oncol. VL - 8 UR - https://doi.org/10.2217/fon.11.138 DO - 10.2217/fon.11.138 ID - Hess2012 ER - TY - JOUR AU - Heiss, M. M. PY - 2010 DA - 2010// TI - The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial JO - Int. J. Cancer. VL - 127 UR - https://doi.org/10.1002/ijc.25423 DO - 10.1002/ijc.25423 ID - Heiss2010 ER - TY - JOUR AU - Linke, R. AU - Klein, A. AU - Seimetz, D. PY - 2010 DA - 2010// TI - Catumaxomab: clinical development and future directions JO - MAbs. VL - 2 UR - https://doi.org/10.4161/mabs.2.2.11221 DO - 10.4161/mabs.2.2.11221 ID - Linke2010 ER - TY - JOUR AU - Ragupathi, G. PY - 2003 DA - 2003// TI - Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21 JO - Clin. Cancer Res. VL - 9 ID - Ragupathi2003 ER - TY - JOUR AU - Navid, F. AU - Santana, V. M. AU - Barfield, R. C. PY - 2010 DA - 2010// TI - Anti-GD2 antibody therapy for GD2-expressing tumors JO - Curr. Cancer Drug Targets VL - 10 UR - https://doi.org/10.2174/156800910791054167 DO - 10.2174/156800910791054167 ID - Navid2010 ER - TY - JOUR AU - Egeter, O. AU - Mocikat, R. AU - Ghoreschi, K. AU - Dieckmann, A. R. M. PY - 2000 DA - 2000// TI - Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice JO - Cancer Res. VL - 60 ID - Egeter2000 ER - TY - JOUR AU - Schüler, T. AU - Qin, Z. AU - Ibe, S. AU - Noben-Trauth, N. AU - Blankenstein, T. PY - 1999 DA - 1999// TI - T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice JO - J. Exp. Med. VL - 189 UR - https://doi.org/10.1084/jem.189.5.803 DO - 10.1084/jem.189.5.803 ID - Schüler1999 ER - TY - JOUR AU - Lüking, C. PY - 2008 DA - 2008// TI - Antitumor effector functions of T cells are dependent on in vivo priming and restricted T-cell receptor expression JO - Int. J. Cancer. VL - 122 UR - https://doi.org/10.1002/ijc.23393 DO - 10.1002/ijc.23393 ID - Lüking2008 ER - TY - JOUR AU - Heiss, M. PY - 2005 DA - 2005// TI - Immunotherapy of malignant ascites with trifunctional antibodies JO - Int. J. Cancer. VL - 117 UR - https://doi.org/10.1002/ijc.21165 DO - 10.1002/ijc.21165 ID - Heiss2005 ER - TY - JOUR AU - Kiewe, P. PY - 2006 DA - 2006// TI - Phase I trial of the trifunctional anti-HER2 × anti-CD3 antibody ertumaxomab in metastatic breast cancer JO - Clin. Cancer Res. VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-05-2436 DO - 10.1158/1078-0432.CCR-05-2436 ID - Kiewe2006 ER - TY - JOUR AU - Boussiotis, V. A. PY - 1994 DA - 1994// TI - Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor JO - Science VL - 266 UR - https://doi.org/10.1126/science.7973657 DO - 10.1126/science.7973657 ID - Boussiotis1994 ER - TY - JOUR AU - Linsley, P. S. AU - Ledbetter, J. A. PY - 1993 DA - 1993// TI - The role of the CD28 receptor during T cell responses to antigen JO - Annu. Rev. Immunol. VL - 11 UR - https://doi.org/10.1146/annurev.iy.11.040193.001203 DO - 10.1146/annurev.iy.11.040193.001203 ID - Linsley1993 ER - TY - JOUR AU - Adam, C. AU - Mysliwietz, J. AU - Mocikat, R. PY - 2007 DA - 2007// TI - Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine JO - J. Transl. Med. VL - 5 UR - https://doi.org/10.1186/1479-5876-5-16 DO - 10.1186/1479-5876-5-16 ID - Adam2007 ER - TY - JOUR AU - Zobywalski, A. PY - 2007 DA - 2007// TI - Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70 JO - J. Transl. Med. VL - 5 UR - https://doi.org/10.1186/1479-5876-5-18 DO - 10.1186/1479-5876-5-18 ID - Zobywalski2007 ER -